Eiger Biopharmaceuticals Says On April 2, Received Notice From Nasdaq That Co's Common Stock Will Be Delisted From Nasdaq; Common Stock Is Expected To Begin Trading On Over-Counter Market On April 11
Eiger Biopharmaceuticals Says On April 2, Received Notice From Nasdaq That Co's Common Stock Will Be Delisted From Nasdaq; Common Stock Is Expected To Begin Trading On Over-Counter Market On April 11
艾格生物製藥公司於4月2日表示，已收到納斯達克的通知，該公司的普通股將從納斯達克退市；普通股預計將於4月11日開始在場外市場上交易
Eiger Biopharmaceuticals Says On April 2, Received Notice From Nasdaq That Co's Common Stock Will Be Delisted From Nasdaq; Common Stock Is Expected To Begin Trading On Over-Counter Market On April 11
艾格生物製藥公司於4月2日表示，已收到納斯達克的通知，該公司的普通股將從納斯達克退市；普通股預計將於4月11日開始在場外市場上交易
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。